The first ranibizumab biosimilar (Byooviz) has potential to alleviate financial burden associated with retinal conditions, but may not be the only new approval for ophthalmology treatment in 2022, explains Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars for Cardinal Health.
Cardinal Health is a multinational health care services company that specializes in the distribution of pharmaceuticals and medical products. The Center for Biosimilars® spoke with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars for Cardinal Health, about the FDA’s recent approval of the ranibizumab biosimilar Byooviz, a product developed by Samsung Bioepis and slated for commercialization by Biogen.
Marketing of this product is not expected to commence before June 2022, but Samsung Bioepis and Biogen hope to use that time to build awareness of the product and lay the groundwork for strong acceptance of what will be the first ranibizumab biosimilar in the United States and possibly elsewhere, too.
In this interview, Oskouei, who is also an Advisory Board member for The Center for Biosimilars®, discusses the strong need for affordable treatment options in the ophthalmology space and the value proposition that Byooviz brings to the table. The originator ranibizumab, Lucentis, is many times more costly than bevacizumab (Avastin), another anti–vascular endothelial growth factor (VEGF) treatment option that has a long history of success in treatment of potentially blinding eye disease.
The big question is the discount from originator price that will accompany this biosimilar launch and what rationale eye disease specialists will use in deciding when to use this product, Oskouei explains.
Also important to consider, she says, is that biosimilars are newcomers in the ophthalmology space, and many stakeholders will be facing the choice of biosimilars for the first time. “I think that’s going to be a key part of how this product and other ophthalmology biosimilars perform in the market,” she says.
The timing of launch, which depends on a licensing agreement between Samsung Bioepis, Biogen, and the originator company, Genentech, offers a window during which novel treatment compounds may enter the picture, potentially adding to the complex dynamics that will affect the market reception for Byooviz, she adds.
As part of its coverage of this event, The Center for Biosimilars® also spoke with George Williams, MD, clinical spokesperson for the American Academy of Ophthalmology. In addition, a text story about the FDA approval is also available.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.